In Vitro Diagnostic Industry’s Political Playbook Rewritten As Firms Lobby On COVID-19 Legislation
Diagnostic companies spent tens of thousands of dollars to influence outcome of coronavirus bills in February, March
Test kit and lab firms spent tens of thousands of dollars in the first quarter of 2020 lobbying legislators to win provisions in coronavirus protection laws to ensure COVID-19 diagnostics would be a top US legislative priority.
You may also be interested in...
A bill that would promote genetic testing for infants and children, introduced by California Rep. Eric Swallwell, is gaining support in the US House of Representatives.
The American Clinical Laboratory Association (ACLA) may proceed with a lawsuit against the US Department of Health and Human Services, an appeals court has ruled. The suit alleges that the agency is setting lab test payment rates unfairly.
Clinical labs are troubled by the idea of granting US FDA vast discretion to determine if laboratory-developed tests (LDTs) are analytically and clinically valid, a key feature of the draft US VALID Act, while in vitro diagnostic kit manufacturers want some clarifications and more flexibility written into the proposal for diagnostic regulatory reforms.